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Abstract
Background: Bronchiolitis caused by the respiratory syncytial virus (RSV) in infants less than two years old is a growing
public health concern worldwide, and there is currently no safe and effective vaccine. A major component of RSV
nucleocapsid, the nucleoprotein (N), has been so far poorly explored as a potential vaccine antigen, even though it is a
target of protective anti-viral T cell responses and is remarkably conserved between human RSV A and B serotypes. We
recently reported a method to produce recombinant N assembling in homogenous rings composed of 10–11 N subunits
enclosing a bacterial RNA. These nanoparticles were named sub-nucleocapsid ring structure (N SRS).
Methodology and Principal Findings: The vaccine potential of N SRS was evaluated in a well-characterized and widely
acknowledged mouse model of RSV infection. BALB/c adult mice were immunized intranasally with N SRS adjuvanted with
the detoxified E. coli enterotoxin LT(R192G). Upon RSV challenge, vaccinated mice were largely protected against virus
replication in the lungs, with a mild inflammatory lymphocytic and neutrophilic reaction in their airways. Mucosal
immunization with N SRS elicited strong local and systemic immunity characterized by high titers of IgG1, IgG2a and IgA
anti-N antibodies, antigen-specific CD8
+ T cells and IFN-c-producing CD4
+ T cells.
Conclusions/Significance: This is the first report of using nanoparticles formed by the recombinant nucleocapsid protein as
an efficient and safe intra-nasal vaccine against RSV.
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Introduction
Respiratory syncytial virus (RSV) is a member of the Pneumovirus
genus in the Paramyxoviridae family that causes severe respiratory
tract infections in infants less than two years old and in elderly or
immuno-compromised patients. In fact, RSV induced-bronchiol-
itis is the most common cause of infant hospitalization in the
developed world and is a suspected risk factor of recurrent wheeze
and asthma in later life [1]. Despite the substantial health and
economic burden caused by RSV illness, there is currently no
vaccine available. Several factors are responsible for the lack of an
effective and safe vaccination strategy.
Firstly, the viral infection itself does not lead to protective
immunity and re-infections occur throughout life during winter
epidemics. Besides, as there are various RSV isolates circulating
throughout the world, from serotype A or B, an effective vaccine
should protect against all of them. Secondly, RSV disease is largely
immune mediated and any potential vaccine must avoid
enhancing immunopathology in the lower respiratory tract.
Indeed, in the sixties, a formalin-inactivated (FI)-RSV vaccine
caused a dramatic increase in the severity of naturally acquired
disease [2,3]. Two children developed fatal vaccine-enhanced
RSV disease, characterized by pulmonary neutrophilia and
eosinophilia. Therefore an effective vaccine needs to limit viral
replication without causing disease exacerbation due to the
obstruction of the airways with inflammatory cells. Thirdly, the
primary targets of a potential vaccine are infants 0–6 months old
and issues such as the immaturity of their immune system, the
presence of maternally-derived RSV neutralizing Abs and specific
safety concerns must be addressed.
Since formalin-inactivated virus vaccines caused aggravated
disease upon natural infection, a large array of alternative
vaccination strategies have been tested against RSV during the
last 40 years in terms of viral antigen, delivery system (live
attenuated virus, replicating or non-replicating vectored vaccines,
subunit vaccines), adjuvant and route of administration (parenteral
or mucosal) [4]. These vaccination strategies were mostly
evaluated in rodent experimental models of RSV infection and
sometimes in non human primates or cattle (natural host of bovine
RSV). Murine studies have been very useful for defining and
characterizing immunogenic RSV antigens, and for deciphering
the immune correlates of protection versus disease exacerbation
[5].
Among the most immunogenic RSV proteins, the F and G
envelope glycoproteins are the targets of neutralizing antibodies
(Ab) [6,7]. A variety of subunit, vectorized or DNA vaccines,
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various stages of development [4]. However, recombinant G and F
or chimeric FG were often found to cause enhancement of lung
pathology upon RSV challenge, in association with the priming of
Th2 cells [4]. Apart from the protective role of neutralizing
antibodies, experimental studies in calves [8] and in mice [9]
indicated that CD8
+ T cells are required for the resolution of an
acute primary RSV infection and are also protective against
vaccine-driven lung eosinophilia following RSV infection [10,11].
Internal viral proteins are the main antigenic targets of RSV-
specific CTL responses, among which the nucleoprotein N is a
major carrier of CTL epitopes in human and cattle [12–15].
Furthermore N is the most conserved viral protein between RSV
human isolates and it even shares <94% amino acid identity
between bovine and human RSV [16]. Thus a vaccine with N as
an antigen might protect against both bovine and human RSV.
Contrary to F or G, the N nucleocapsid protein of RSV has
been poorly explored as a vaccine antigen and, when so, only
under the form of virus-vectorized [17,18] or free DNA vaccine
co-administered with plasmid DNA encoding the fusion protein F
[19,20]. These vaccination strategies efficiently triggered protec-
tive T cell responses. Nevertheless the protection afforded by
recombinant vaccinia virus (rVV) expressing N against viral
replication was not as strong as the one afforded by rVV-F or
rVV-G [17]. Plasmid DNA vaccine encoding N and F conferred
partial protection against RSV challenge in terms of clinical score
and virus load in infant rhesus monkeys [19] or in calves [20], but
the respective role of F and N viral immunogens in the protection
was not investigated. One hypothesis for the moderate efficacy of
N as a vaccine antigen may be its mode of delivery via plasmid
DNA or rVV. Recently, a recombinant form of the nucleocapsid
protein from the measles virus, another paramyxoviridae, was
shown to prime protective anti-viral CD8
+ CTL after a single
topical immunization via the buccal mucosa [21]. Due to its strong
tendency to form nucleocapsid-like super-structures, the N protein
from RSV used to be difficult to produce in large amounts as a
soluble recombinant protein. Recently, Tran et al. in our
laboratory, have developed an original technology to produce
and purify N, co-expressed in E. coli with the C-terminal fragment
of the RSV phosphoprotein (PCT) fused to glutathione S-
transferase. The strong interaction between PCT and N allows
the purification of recombinant N, which assembles in homoge-
nous rings (diameter 15 nm), composed of 10–11 N subunits
entrapping a stretch of 70 nucleotide-long bacterial RNA. These
nanoparticles were named ‘‘N SRS’’ for sub-nucleocapsid ring
structures [22]. Thus we made the hypothesis that a N SRS sub-
unit vaccine could provide better protection than the previous
vaccination assays with N and safer protection than the previous F
and G sub-unit vaccines.
Intranasal vaccination against RSV represents an attractive
approach in order to prevent virus spreading to the lower
respiratory tract since host immune cells are likely to be primed in
the relevant regional lymphoid tissues. However, the mere
introduction of non-replicating antigens into the respiratory tract
has often proven insufficient at inducing T cell responses. Yet, co-
administration of antigens with bacterial enterotoxins, like
Escherichia coli heat labile enterotoxin (LT), promotes local and
systemic Ab responses and augments Ag-specific T cell responses
[23]. For instance, a mutant derivative of LT, named LT(R192G),
when administered intra-nasally with viral epitopes/antigens was
shown to induce mixed Th1 and Th2 cellular immunity, and
CD8
+ CTL responses [24–27].
In the present study, we present experimental data showing that
N SRS nanoparticles can be rapidly engulfed by murine
macrophage and dendritic cell lines. Furthermore we demonstrate
that intranasal delivery of N SRS, together with the mucosal
LT(R192G) adjuvant, primed adult BALB/c mice for Ab, CD4
and CD8 mediated T cell responses and conferred protective
immunity against viral replication. Following virus infection, a
mild inflammatory infiltration of the lungs by lymphocytes and
neutrophils occurred, with activated CD4
+ and CD8
+ T cell
subsets being both recruited to the airways.
Results
Fluorescent N SRS complexes are rapidly internalized by
murine cell lines with antigen-presentation ability
In order to test whether N SRS complexes could target cells of
the murine respiratory tract involved in antigen presentation, we
studied the internalization by one macrophage and one dendritic
cell line of fluorescent N SRS obtained by fusing the green-
fluorescent-protein (GFP) at the C-terminus of N. The N-GFP
chimeric protein was expressed in E. coli and purified according to
the procedure previously described for N SRS [22]. The GST-
PCT+N-GFP complex was purified to .95% homogeneity, as
estimated by SDS-PAGE and Coomassie brilliant blue staining
(Fig. 1A). Analysis of the purified complex adsorbed on
glutathione-Sepharose beads under UV light revealed a strong
green fluorescence for GST-GFP and GST-PCT+N-GFP, and no
visible fluorescence for GST-PCT+N (Fig. 1B), indicating that the
GFP fused at the C-terminus of N was correctly folded. To further
characterize the PCT+N-GFP complex and determine whether it
is constituted by SRS as it is the case for PCT+N, the samples were
analyzed by negative-staining electron microscopy. Complexes
containing N-GFP appeared mostly as ring-like structures with a
less regular shape than SRS containing N only (Fig. 1C).
First, we used flow cytometry to check the capture of N-GFP
SRS by murine macrophages (RAW) or dendritic cells (D2SC/1).
As shown Fig. 1D, N-GFP SRS fluorescence was associated to cells
after one hour of contact at 4uC. Only background level
fluorescence was detected for cells incubated with soluble GFP.
To demonstrate the internalization of N-GFP SRS by confocal
microscopy, cells were incubated for one hour at 37uC with N-
GFP SRS and then fixed and stained for filamentous actin with
phalloidin-rhodamin (red). Punctuated green fluorescence was
observed inside the cells for both cell lines (Fig. 1E). No signal was
observed in cells incubated with soluble GFP (not shown).
Therefore, N SRS nanostructures are rapidly internalized by
phagocytic antigen-presenting cells, presumably in endosomal
compartments as suggested by the punctuated fluorescence.
Nasal vaccination with N SRS protects against an RSV
challenge
We investigated whether the delivery of N SRS nanostructures
with the mucosal adjuvant LT(R192G) to adult BALB/c mice can
induce protective immunity against a viral challenge with the
human RSV-A2 strain.
Non vaccinated (control) mice and mice administered twice
intra-nasally (i.n.) LT(R192G) or N SRS+LT(R192G), 4 and
2 weeks before, were infected i.n. with RSV-A2 and killed from 4
to 10 days post-infection. A quantitative real-time RT-PCR,
targeting viral N-RNA among total lung RNA was used to assess
viral replication in lung tissue. As shown Fig. 2A, i.n. vaccination
with N SRS+LT(R192G) (black bars) reduced very significantly
the amount of N-specific RNA detected in lung RNA extracts (3-4
Log reduction at day 4, 5 and 6 p.i., p,0.001 and 2 Log reduction
at day 10 p.i., p,0.05). A slight but transient decrease in N-RNA
was also observed in mice administered twice the LT(R192G)
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PLoS ONE | www.plosone.org 2 March 2008 | Volume 3 | Issue 3 | e1766Figure 1. N-GFP fusion protein assembles into fluorescent SRS that are internalized by murine macrophage and dendritic cell lines.
(A) SDS-PAGE analysis of purified GST-PCT+N-GFP complex. Sample (1) was denatured in Laemmli buffer, run on a 12% polyacrylamide gel and
detected with Coomassie brilliant blue staining. (2) protein molecular size standards (kDa). (B) Observation of the different complexes adsorbed on
glutathione-Sepharose 4B beads under UV light. (C) Electron micrographs of ring-like structures produced by heterologous expression of N-GFP (left)
and N (right) purified by GST-PCT. Bars, 50 nm. (D) N-GFP SRS (thin line) adsorption by RAW and D2SC/1 cell lines after 1 hour incubation at 4uC
(controls: PBS in grey or GFP bold line). Green fluorescence associated with living cells was analyzed by flow cytometry (the gate was set up excluding
dead cells stained with propidium iodide in FL3). The data (100,000 events) were acquired with a FACScalibur and analyzed with Cell Quest-Pro. (E)
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p,0.05).
We also investigated whether sub-cutaneous administration of N
SRS+LT(R192G) vaccine conferred any protection. Interestingly,
mice vaccinated parenterally displayed only one Log reduction in
their viral load at day 5 compared to non vaccinated animals
(p,0.01) (Fig. 2B). Therefore the priming of local immune
effectors by nasal vaccination seemed required in order to
efficiently protect the mice against RSV replication.
Non vaccinated mice did not show any significant weight loss or
illness from day 2 to day 10 after virus challenge (Fig. 2C), which is
expected in a primary RSV infection [28]. Body weight loss is also
an important parameter described in the literature for measuring
the exacerbated illness caused by RSV vaccine based on the G or
F envelope proteins [28]. Mice vaccinated i.n. with N SRS did not
lose more weight than non vaccinated mice upon RSV challenge
(Fig. 2C), thus showing that our vaccination strategy did not cause
disease exacerbation upon virus infection.
Nasal vaccination with N SRS triggers a mild
inflammatory reaction in airways upon RSV infection
A major obstacle for vaccination against RSV is the risk of
inducing an exacerbated lower respiratory tract disease due to an
enhanced local inflammatory reaction following viral infection.
r
Confocal microscopy analysis showing entry of N-GFP SRS (green fluorescence) within cells. Filamentous actin was stained with phalloidin Rhodamin
(red). Images of individual cells are either z sections through confocal images taken at sequential focal planes or xy views. Stacks of confocal images
were acquired at 0.37 mm intervals (bars 10 mm).
doi:10.1371/journal.pone.0001766.g001
Figure 2. Nasal vaccination with N SRS protects against RSV replication in the lungs without causing disease exacerbation. BALB/c
mice were administered twice at 2 weeks interval i.n. (A) or s.c (B) 10 mg N SRS and 5 mg LT(R192G) (black bars) or 5 mg LT(R192G) alone (grey bars).
Two weeks after the second immunization, mice were challenged with 10
7 PFU hRSV strain A2, together with a non-immunized control group of mice
(white bars). Mice were monitored daily for body weight. Viral replication in lung was monitored by quantitative real-time RT-PCR. The number of N-
specific RNA copies for 1 mg total reverse-transcribed lung RNA was determined against a standard curve using a plasmid encoding the viral N gene.
(A) Intranasal immunization with N SRS reduced N-specific RNA in lungs 4 to 10 days after RSV challenge. (B) Sub-cutaneous vaccination induced
moderate protection at 5 days after RSV challenge. Each bar represents the mean and SEM of 5–8 mice. (C) Weight loss in vaccinated versus non
vaccinated groups is expressed as the percentage of initial weight (plot of mean6SEM, n=4–5, day 0 is 100%). Data are representative from four
independent experiments.
doi:10.1371/journal.pone.0001766.g002
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not show illness upon RSV challenge, we nevertheless investigated
more closely for signs of inflammatory reaction in broncho-
alveolar lavage (BAL) or lung tissue.
To assess pulmonary tissue infiltration, paraffin-embedded lung
sections were stained with hematoxylin and eosin and carefully
examined. Five days after RSV infection, lung sections from non
vaccinated control mice showed diffuse peribronchiolar infiltrates
(Fig. 3B, white arrow). Compared to these small lesions, lung
sections from mice having received only the adjuvant (Fig. 3C) or
the complete vaccinal preparation N SRS+LT(R192G) (Fig. 3D)
displayed larger peribronchiolar and perivascular immune infil-
trates (white arrows) mostly composed of lymphocytes. Few
neutrophils were present within the lymphocytic infiltrates of lung
sections from N SRS vaccinated mice (Fig. 3E, black arrows). No
cellular infiltrate was found in the lung parenchyma, whatever the
immunization treatment (Fig. 3). Thus N SRS vaccination caused
a mild lung inflammatory reaction in contrast to the severe lung
lesions and disease exacerbation reported in the literature for RSV
vaccine based on the G surface protein [28].
We also investigated which subsets of cells were recruited in the
broncho-alveolar lumen following RSV infection of vaccinated
mice. The total number of viable cells recovered from the BAL at
5 days post challenge was markedly enhanced for LT(R192G) and
even more for N SRS+LT(R192G) vaccinated mice (Table 1).
After cytocentrifugation and May-Gru ¨nwald-Giemsa staining of
BAL cells collected at days 0, 5 and 10 post RSV challenge (Fig. 4),
we observed that 2 administrations of LT(R192G) alone or N
SRS+LT(R192G) had increased significantly the percentages of
lymphocytes in BAL compared to the control non vaccinated
group (Fig. 4 and Table 1). Moreover, virus challenge of mice
vaccinated with N SRS+LT(R192G) resulted in an increased
percentage of neutrophils in BAL compared to non vaccinated
mice or mice treated with LT(R192G) only (Fig. 4 and Table 1).
Yet, at no time point was there any significant presence of
eosinophils in the BAL of any group.
Nasal vaccination with N SRS generates antigen-specific
CD4
+ and CD8
+ T cell in spleen and regional lymph nodes
The nucleocapsid protein when expressed by recombinant
vaccinia virus is known to be an important target for cellular
responses, both in mice [15] and calves [12]. We thus wondered
whether N SRS would generate antigen-specific CD4
+ and/or
CD8
+ T responses in mice.
CFSE-stainedsplenocytesfromnonvaccinated,LT(R192G)orN
SRS+LT(R192G)immunized micewereco-culturedwitheitherlive
RSV, N SRS or medium alone and after 7 days the level of CFSE
staining on CD4
+ and CD8
+ cell subsets was quantified by flow
cytometry analysis (Fig. 5A). A large percentage of CD4
+ and CD8
+
splenocytes isolated from N SRS immunized mice and co-cultured
with N SRS or RSV displayed low CFSE fluorescence, showing the
expansion of CD4
+ and CD8
+ N-specific T cells (Fig. 5A red lines).
To control for the specificity of this response, we showed that CD4
+
and CD8
+ splenocytes isolated from non immunized mice (grey
lines) or LT(R192G) treated mice (black lines) did not proliferate in
response to either RSV or N SRS (Fig. 5A).
To get further insights into the function of these antigen-specific
CD4
+ and CD8
+ T cells, splenocytes from individual mice or
pooled draining lymph node cells were re-stimulated in vitro for
72 hr with N (10 mg/ml) or medium (negative control). IFN-c was
assayed in cell culture supernatants by specific sandwich ELISA.
Two nasal administrations of N SRS and LT(R192G), two weeks
apart, elicited memory Ag-specific IFN-c producing cells in spleen
and to a lesser level in the respiratory tract-draining lymph node
(LN) (Fig. 5B). Besides, we could not detect IL-5 nor IL-10 in the
same cell culture supernatant, whereas these cytokines were
readily detected in PMA and ionomycine stimulated spleen or
lymph node cell supernatants (data not shown).
In order to distinguish between CD4
+ and CD8
+ T cells as IFN-
c sources, splenocytes were depleted in either subset by magnetic-
beads separation. The frequency of Ag-specific IFN-c producing
cells in total, CD4
+ or CD8
+ depleted cell populations was
monitored by ELISPOT upon 20 hr co-culture with N SRS. We
found that IFN-c producing cells were nearly absent from CD4
+-
depleted splenocytes and that their frequency was slightly
increased in CD8
+-depleted splenocytes (Fig. 5C). These data
clearly demonstrate that N SRS nasal vaccination primed antigen-
specific IFN-c producing CD4
+ T cells.
Thus we can conclude that N SRS mucosal immunization
elicited both CD4
+ and CD8
+ antigen-specific memory responses,
with a Th1 cytokine secretion pattern.
Figure 3. Nasal vaccination with N SRS and LT(R192G)
augments cellular infiltration in lung tissue. BALB/c mice were
administered i.n. 10 mg N SRS and/or 5 mg LT(R192G), twice at two
weeks interval. Two weeks after the second immunization, all animals
were challenged with 10
7 PFU hRSV strain A2, together with a control
group of non-immunized mice. One group of mice was neither
immunized nor infected. Lung were dissected out 5 days post
challenge, embedded in paraffin, sectionned at 7 mm and stained with
eosin-hematoxylin. One representative section per group is shown
(original magnification 206, bars 100 mm). (A) control group (no
vaccine, no virus), (B) primary infection group (no vaccine, RSV); (C)
adjuvant only group (LT(R192G), RSV), (D) N SRS vaccinated group (N
SRS+LT(R192G), RSV). Areas with an infiltration of inflammatory cells are
indicated with a white arrow. (E) Enlargement showing that the
immune infiltrate in N SRS vaccinated group was composed predom-
inantly of lymphocytes and some neutrophils (black arrows) (original
magnification 63x, bars 20 mm).
doi:10.1371/journal.pone.0001766.g003
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results in the presence of activated CD4
+ and CD8
+
lymphocytes in airways
We then wondered if the memory N-specific CD4
+ and CD8
+ T
cells induced by vaccination would generate effector cells at the
site of virus replication, that is the airways. To answer this
question, BAL cells collected before and 4–10 days post infection
were stained with anti-CD69 (early activation marker) in
combination with either anti-CD4 or anti-CD8 and analyzed by
flow cytometry.
The CD8
+ and CD4
+ lymphocytes recovered in BAL from non
infected mice, two weeks after booster immunization with
LT(R192G) or N SRS+LT(R192G) were mostly CD69
2
(Fig. 6A, n.i.) and expressed high levels of CD44 (data not shown),
such phenotype corresponding to memory cells. RSV infection of
either non vaccinated, LT(R192G) or N SRS+LT(R192G)
vaccinated mice induced a massive activation of BAL CD4
+ or
CD8
+ lymphocyte subsets, with CD69 being expressed on more
than 50% of the gated cells (Fig. 6A, day 10). The proportion of
CD4
+ and CD8
+ cells among CD69
+ lymphocytes is shown
(Fig. 6B) 10 days after virus infection. Interestingly activated
CD69
+ BAL lymphocytes from N SRS vaccinated mice were
equally composed of CD8
+ and CD4
+ cells whereas CD69
+ BAL
lymphocytes from non vaccinated or LT(R192G) immunized mice
were mostly CD8
+ (Fig. 6B). The total number of CD4
+CD69
+ or
CD8
+CD69
+ lymphocytes in BAL 4 and 10 days after RSV
challenge is shown (Fig. 6C). Intra-nasal immunization with N
SRS was specifically associated with the presence of CD4
+CD69
+
lymphocytes as early as 4 days and up to 10 days after virus
infection (Fig. 6C), as compared with non vaccinated or
LT(R192G) immunized mice where CD8
+CD69
+ lymphocytes
were the predominant subset (Fig. 6C).
Thus, virus challenge of mice vaccinated intra-nasally with N
SRS+LT(R192G) was characterized by a balanced infiltration of
CD8
+CD69
+ and CD4
+CD69
+ lymphocytes in the airways,
among which the CD4
+CD69
+ subset presumably reflected the
priming of N-specific CD4
+ T cells upon vaccination.
Nasal vaccination with N SRS elicits systemic and
mucosal N-specific IgG1, IgG2a and IgA antibodies
Intranasal administration of N SRS and LT(R192G) to adult
BALB/c mice induced N-specific antibody responses, as assayed
Figure 4. Nasal vaccination with N SRS induces neutrophil and lymphocyte recruitment in BAL. BALB/c mice were administered i.n.
10 mg N SRS and/or 5 mg LT(R192G) twice at two weeks interval. One group was not immunized. Two weeks after the second immunization, all
animals were challenged with 10
7 PFU hRSV strain A2. Cellular composition of BAL sampled at 0, 5 and 10 days after RSV challenge as determined by
May-Gru ¨nwald-Giemsa staining: lymphocytes (dotted bars), macrophages (white bars) and neutrophils (grey bars). Results are expressed as mean and
SEM percentages from 5–8 individual mice (Data from two experiments with similar results).
doi:10.1371/journal.pone.0001766.g004
Table 1. Inflammatory cellular infiltrate in BAL, 5 days after RSV challenge
Number of cells (610
4)
(a) % lymphocytes
(b) % neutrophils
(b)
(1) No vaccine 3.760.7 (n=5) 14.364.3 (n=8) 2.260.7 (n=8)
(2) LT(R192G) 8.361.5 (n=4) 37.965.4 (n=8) 3.161.8 (n=8)
(3) NS R S +LT(R192G) 15.563.6 (n=4) 28.461.8 (n=7) 22.962.5 (n=7)
p (U Mann-Whitney)
(1) versus
(2) ,0.05
(1) versus
(2) ,0.01
(1) versus
(2) ns
(1) versus
(3) ,0.05
(1) versus
(3) ,0.05
(1) versus
(3) ,0.001
(2) versus
(3) ns
(2) versus
(3) ns
(2) versus
(3) ,0.001
(a)viable cells were counted after tripan blue exclusion of dead cells.
(b)% was determined after May-Gru ¨nwald-Giemsa coloration.
doi:10.1371/journal.pone.0001766.t001
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PLoS ONE | www.plosone.org 6 March 2008 | Volume 3 | Issue 3 | e1766Figure 5. T cell-mediated immune response to N SRS. Nasal vaccination with N SRS generated antigen-specific CD8
+ T cells and IFN-c
producing CD4
+ T cells. (A) Antigen-specific proliferation of CD4
+ and CD8
+ T splenocytes after 7 days restimulation with RSV-A2 (1 PFU/cell), N
(10 mg/ml) or medium. Pooled splenocytes from non immunized (grey lines), LT(R192G) (black lines) or N SRS+LT(R192G) (red lines) immunized
groups were stained with CFSE, cultured for 7 days and then labeled with anti-CD8-biot and anti-CD4-PE for flow-cytometry analysis. The data
(100,000 events) were acquired with a FACScalibur and analyzed with Cell Quest-Pro. The CD8
+ or CD4
+ lymphocyte population was gated according
to SSC/FCS and FL4 (CD8) or FL2 (CD4) fluorescence criteria and the fluorescence corresponding to CFSE was monitored in FL1. The percentage of
Nasal N Vaccine against RSV
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primary and secondary immunization (Fig. 7). A single immuni-
zation with N SRS and adjuvant resulted in significant production
of anti-N Ab in serum and a secondary type of response was
detected after a second i.n. administration two weeks later (Fig. 7A:
day 0 versus day 14 and day 14 versus day 28 p,0.05, n=5). N
SRS immunization elicited both IgG1 and IgG2a serum
antibodies, with IgG1 titers being 5 times higher than IgG2a
titers two weeks after the boost (p,0.01 Fig. 7B), thus suggesting a
mixed Th1/Th2 type of immune response. Finally two successive
nasal immunizations with N SRS also elicited strong local Ig
responses dominated by the IgA isotype in BAL (Fig. 7C). Sub-
cutaneous administration of N SRS and LT(R192G), two weeks
apart, elicited similar levels and pattern of antibody responses in
serum but failed to prime for anti-N IgA in BAL (data not shown).
Systemic and mucosal antibodies elicited against N SRS were also
able to recognize the native viral N as shown by their specific
binding to RSV-infected HEp2 cells (Fig. 7D). We tested whether
serum and BAL N-specific antibodies had the capacity to
neutralize RSV-A2 replication in vitro on HEp-2 monolayers with
or without 2% guinea-pig complement (Sigma). Negative controls
were serum and BAL Ig harvested from non-immunized mice and
the positive control was goat anti-RSV antibodies (Serotec). We
found no evidence of virus neutralization by serum and BAL
antibodies to N as compared to positive and negative controls
(data not shown). It is thus unlikely that the antibody response
primed upon N SRS vaccination will play a direct role in the
protection against virus infection.
Discussion
Early attempts at vaccinating children against RSV infection
using a formalin inactivated virus resulted in a dramatic
aggravation of disease, linked to the exacerbation of inflammatory
reactions in the lower respiratory tract. Hence, despite more than
40 years of intense research, there is still no vaccine licensed
against human RSV, although some live attenuated RSV vaccines
obtained by reverse genetic have now reached the stage of clinical
trials in infant cohorts [29]. However, in a context where even wild
type RSV infections fail to induce a strong long lasting protective
immunity, these recombinant RSV vaccines, which can be less
immunogenic than the wild type virus because of attenuation, may
not bring the final clue to the issue of RSV vaccination.
Conversely subunit vaccines have the advantage of safety, but
need to be formulated and delivered appropriately in order to
induce the desired magnitude and quality of immune responses.
Ideally a vaccine against RSV should prevent virus dissemination
from the upper to the lower airways, thus reducing the intensity of
the inflammatory detrimental immune response in the lungs.
We are the first to propose an efficient vaccination strategy
against RSV using the nucleocapsid protein alone as a vaccine
antigen, under the form of soluble nanoparticles composed of 10–
11 N units assembled around a bacterial RNA (referred to as N
SRS). In the present study we have demonstrated that N SRS are
highly immunogenic when delivered via the nasal route together
with LT(R192G) and that the immune response primed upon
vaccination is protective against an RSV challenge. Work is in
progress to show the immunogenicity of N SRS in newborn calves
and mice, that is at the period of life when the immune system is
considered to respond poorly to vaccination [30].
The strong immunogenicity of N SRS nanoparticles could be
due to their highly organized and repeated structure, as was
reported for the core proteins of the human hepatitis B virus [31],
the Measles virus [21], and the Newcastle disease virus [32].
Moreover we demonstrated in the present study that N SRS were
rapidly taken up by dendritic cell and macrophage cell lines
representing key subsets for the induction of immune responses in
the respiratory tract. These observations are in agreement with the
findings by others demonstrating that the nucleocapsid protein of
measles virus binds to different cells types (dendritic cells,
monocytes and epithelial cells,) and that at least two receptors
are implicated in this process: FccRII/III and a second one not yet
identified [33]. We are now investigating the mechanisms by
which N SRS are taken up by macrophage or dendritic cells,
whether or not N SRS internalization involves a specific receptor
and what are the consequences of N SRS engulfment by airway
dendritic cells in term of maturation and pathway of antigen
presentation. Potentially, once N SRS are internalized and
processed by dendritic cells, the bacterial RNA they contain,
could be made accessible for cellular receptors such as TLR7 or
TLR8 and provide the signaling for maturation [34].
The most important finding of our study was to demonstrate
that two successive nasal immunizations with N SRS and
LT(R192G) at 2 weeks interval, drastically reduced RSV replica-
tion in the lungs, without causing disease exacerbation. However,
an enhanced inflammatory response to virus infection was
recorded in the airways, with an infiltration of lymphocytes and
neutrophils in the BAL and in the peribronchovascular spaces.
We also showed that sub-cutaneous delivery of N SRS and
LT(R192G) was far less efficient at stimulating protective
immunity against RSV than the intra-nasal delivery. Thus we
can conclude that a mucosal route of antigen delivery is required
in order to prime local immune effectors. As CTL directed against
N epitopes were shown to be protective against RSV infection in
cattle and mice [17,18], we anticipated that nasal vaccination with
N SRS would elicit antigen-specific memory CD8
+ T lympho-
cytes. We have indeed recorded a memory CD8
+ T cell response
in spleen following immunization with N SRS. N SRS
immunization also induced antigen-specific IFN-c producing
CD4
+ memory cells in spleen and regional lymph nodes. Upon
viral challenge of vaccinated mice, effector CD4
+ and CD8
+
lymphocytes were rapidly recruited to the BAL. Finally, nasal
immunization with N SRS generated strong local and systemic Ab
responses, including a massive anti-N IgA Ab production in BAL.
r
proliferating cells (low CFSE staining) is indicated on the plot with the color corresponding to the immunization condition. (Data from one out of two
experiments with similar results). (B) Two weeks after the booster immunization with LT(R192G) or N SRS+LT(R192G), spleen (white bars) and draining
LN (cervical and sub-maxilliary LN, black bars) were dissected out and cell suspensions prepared. Splenocytes from individual mice and pooled
draining LN cells from each group of mice were re-stimulated for 72 hr with N SRS (10 mg/ml) or medium (mock). IFN-c secretion was measured in cell
culture supernatant with a standardized specific sandwich ELISA assay (white bars represent the mean and SEM of 5 individual spleens, black bars
represent the pool of LN, data from one out of three experiments). (C) The frequency of IFN-c secreting splenocytes after 20 hr restimulation with N
(10 mg/ml) was monitored by ELISPOT. Spleen cells from LT(R192G) or N SRS+LT(R192G) immunized mice were assayed for each mouse (each bar
represents the mean and SEM of 5 mice). Depletion of CD4
+ or CD8
+ T cells was done by immuno-magnetic separation of pooled splenocytes from
either LT(R192G) or N SRS+LT(R192G) groups. (Data from one out of two experiments with similar results).
doi:10.1371/journal.pone.0001766.g005
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We can draw several hypothesis from these observations about
the role of the immune effectors primed by N SRS nasal
vaccination in the viral clearance.
First, a previous report with another modified LT (LTK63)
delivered alone intranasally demonstrates its capacity to reduce the
inflammatory lesions caused in lung tissue by respiratory virus
infections [35]. This phenomenon, called innate imprinting,
reduces as well virus replication in lungs following Influenza or
RSV infection [35]. Therefore LT(R192G) may have contributed
by similar mechanisms to the partial protection we observed
against RSV replication. However, in our experimental condi-
tions, LT(R192G) triggered an increased CD8
+ lymphocytic
infiltration of the airways upon virus challenge. Whether this
priming for CD8
+ cells is beneficial or detrimental to the outcome
Figure 6. Nasal vaccination with N SRS followed by virus infection triggers CD69
+CD4
+ and CD69
+CD8
+ lymphocytes recruitment in
BAL. BALB/c mice were administered i.n. twice at 2 weeks interval 10 mg N SRS and/or 5 mg LT(R192G). Two weeks after the second immunization, N
SRS+LT(R192G) or LT(R192G) treated mice and a control group of non-immunized mice were challenged with 10
7 PFU hRSV strain A2. BAL cells were
collected from non-infected vaccinated mice and at days 4 and 10 post-RSV challenge of vaccinated and control mice. Live cells were numerated after
trypan blue exclusion. Cells (pool of 5 mice per group) were stained with fluorochrome-conjugated Abs anti-CD4, -CD8 and -CD69 and analyzed on a
FACS Calibur, collecting data on at least 5,000 lymphocytes gated according to FSC and SSC criteria. (A) Gated on CD4
+/CD8
+ lymphocytes. First plot
shows matched-isotype background staining for anti-CD69 (pool of BAL, 10 days post-RSV). Second and third dot plots show CD69 staining among
BAL cells from N SRS+LT(R192G) vaccinated mice, respectively non infected (n.i.) or 10 days after RSV infection. The % of CD69
+ cells is indicated on
the plots. (B) Gated on CD69
+ lymphocytes. Percentage of CD4
+ and CD8
+ cells, 10 days after virus challenge of non vaccinated mice (first plot),
LT(R192G) or N SRS+LT(R192G) immunized mice (second and third plots, respectively). The % of CD4
+ and CD8
+ cells are indicated on the plots. (C)
The total number of CD4
+CD69
+ (black bars) and CD8
+CD69
+ (white bars) lymphocytes in BAL was calculated as (% positively stained cells)6(% gated
cells)6(number of live cells) at 4 and 10 days after RSV infection.
doi:10.1371/journal.pone.0001766.g006
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preliminary vaccination trials, N SRS administered without
LT(R192G) failed to protect mice against virus replication.
Second, CD4
+ and CD8
+ T lymphocytes play a major role in
the immune responses to respiratory virus infections (ex influenza
and parainfluenza viruses) [36]. Functional memory CD4
+ T cells
were shown to persist in the lung following respiratory virus
infection and then provide a substantial degree of protection
against secondary infection [37]. This protection is mediated at
least in part by IFN-c and does not depend on antibody [38].
Interestingly IFN-c secreting CD4
+ T cells have already been
shown to be the major protective element against RSV in trials
using the sub-unit vaccine BBG2Na [39].
On the other hand, although the protective role of CD8
+ T cells
against RSV infection is well documented [9], they can provoke
lung-disease exacerbation when in excess, as reported in
vaccination assays with the dominant K
d restricted CTL epitope
from the M2 protein of RSV [40,41]. Conversely, the production
of IFN-c by CD4
+ or CD8
+ T cells down-regulated the
pathological immune mediators in murine experimental models
of vaccine-mediated lung-disease exacerbation [10,42]. Thus, a
moderate CD8
+ T cell priming and a strong Th1 imprinting might
be a clue to why we obtained protection against RSV challenge
with mild inflammation at the lung tissue level.
Third, secretory IgA antibodies play a central role in protecting
mucosal surfaces against infections by blocking the entry of
pathogens into target epithelial cells and/or by forming immune
complexes that will be trapped into mucus, a defense mechanism
referred to as immune exclusion [43]. Since N is not expressed at
the surface of RSV virions, in contrast to the fusion (F) or
attachement (G) protein, anti-N antibodies are not likely to
neutralize RSV via immune exclusion. Indeed anti-N antibodies
Figure 7. Systemic and mucosal antibody response to N SRS administered intra-nasally. BALB/c mice were administred 10 mg N SRS and/
or 5 mg LT(R192G) twice i.n. at two weeks interval. Individual sera were collected at day 0, 14 and 28 and individual BAL supernatants at day 28. (A)
Total Ig, (B) IgG1 (white bars) and IgG2a (black bars) anti N antibodies in serum. (C) total Ig (white bars) and IgA (black bars) in BAL. Titers were
determined in an endpoint dilution ELISA assay on plates coated with N SRS. Each bar represents the mean and SEM of 5–6 mice. Titers are shown
with logarithmic scale (data from one out of three experiments with similar results). (D) Systemic and mucosal antibodies raised against N SRS
recognize RSV-A2. Total Ig, IgG1, IgG2a and IgA in BAL or serum were titrated by ELISA on plates coated with RSV infected HEp-2 versus non infected
HEp-2 cells. Data shown are ODx1000 at dilution 270 for sera samples and dilution 27 for BAL samples, after subtracting OD value of non infected
HEp2. Each bar represents the mean and SEM of 5–6 mice (Data from one out of two experiments with similar results).
doi:10.1371/journal.pone.0001766.g007
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expressing N or after vaccination with N SRS were not
neutralizing ([44] and our data).
Intra-cellular neutralization might be another way for IgA to
neutralize viruses as recently proposed at least in vitro: IgA
antibodies against the inner protein VP6 of rotavirus neutralize
viral replication in the endosomal compartment of target epithelial
cell [45] and IgA directed against measles virus N efficiently block
virus replication in epithelial cells [46]. Thus it can be
hypothesized that the anti-N IgA responses, triggered by nasal
vaccination with N SRS, could limit RSV dissemination by
interfering with its replication inside the cells from the respiratory
tract epithelium. However preliminary passive transfert experi-
ments, either intranasally or intra-peritoneally, with Ig purified
from BAL and serum of N SRS vaccinated mice, did not confer
any significant protection against virus replication.
Finally, the early infiltration of neutrophils that we observed in
BAL upon RSV challenge of vaccinated mice could also
participate to virus clearance. Indeed neutrophils have recently
been described to be implicated in RSV clearance [47].
In the present study we have successfully evaluated a new
subunit vaccination strategy based on intra-nasal delivery of
nanometric sub-nucleocapsid ring structures of RSV. Further
investigations will be required to decipher the exact mechanisms of
the protection we have observed. Knowing the exact pathways by
which a vaccination strategy against RSV is efficient will also help
to minimize the risk of disease exacerbation in the target
population, that is newborn children or newborn calves.
Materials and Methods
Plasmid constructions
The pGEX-P and pET-N plasmids which contain sequences
from the RSV Long strain [48] have been described previously
[49]. For expression of GFP in E. coli, the EGFP gene was
subcloned from pEGFP-N1 (Clontech) at the SmaI-NcoI sites in
pGEX-4T3 (Amersham Biosciences). A pET-N-Sac was derived
from pET-N by introducing a SacI restriction site at the end of the
N-coding sequence by using the Pfu DNA polymerase with the
QuickChange Site-Directed Mutagenesis Kit (Stratagene) accord-
ing to the manufacturer’s instructions (sequence of primers
available on demand). This mutation (GAG CTT–.GAG CTC)
did not modify the amino acid sequence of the two last residues of
N. To insert the EGFP coding sequence in frame at the end of N,
plasmid pET-N was digested by EagI, blunt ended by DNA
polymerase Klenow fragment, and digested by SacI. Plasmid
pEGFP-N1 (Clontech) was digested by EagI, treated with DNA
polymerase I Klenow fragment, digested by SacI, and the EGFP
coding sequence was inserted into pET-N. The resulting plasmid
was designated pET-N-GFP, and encodes for a N-GFP fusion
protein.
The integrity of all constructs was assessed by DNA sequencing.
Expression and purification of recombinant proteins from
E. coli
E. coli BL21 (DE3) (Novagen) cells were co-transformed with
either the plasmids pGEX-P and pET-N or the plasmids pGEX-P
and pET-N-GFP. Recombinant protein expression and purifica-
tion of the GST-fusion proteins was performed with glutathione-
Sepharose 4B beads (Pharmacia) as previously described [22]. This
protocol allows the purification of recombinant N and N-GFP
proteins via their capacity to interact with the C-terminal fragment
of P (residues 161–241) fused to GST (named GST-PCT). N+PCT
and N-GFP+PCT were separated from the beads by thrombin
cleavage as previously described [22]. N and N-GFP were further
purified by gel filtration in order to remove the PCT fragments
[22].
Electron microscopy
Samples containing purified N and N-GFP proteins were
applied to an air-glow-discharged carbon-coated grid and stained
with a 2% uranyl acetate aqueous solution. Grids were observed in
a CM12 electron microscope (Philips) operated at 80 kV.
Micrographs were recorded at a nominal magnification of 35000
on Kodak SO163 Electron Plate, developed 12 min in Kodak
D19. The scanned micrographs were visualized with Photoshop
(Adobe Systems).
Cell lines
The RAW264.7 murine macrophage cell line (given by Dr. H
Bierne, Institut Pasteur, France) was grown in DMEM (Sigma)
supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine,
100U/mL Penicillin and 0.1mg/mL Streptomycin. The D2SC/1
murine splenic dendritic cell line (given by Prof. P. Ricciardi-
Castagnoli, University of Milano, Italy) was grown in Iscove’s
Modified Dulbecco’s medium (Sigma) supplemented with 5%
FCS, 2mM L-glutamine, 100U/mL Penicillin, 0.1mg/mL Strep-
tomycin (PS) and 50 mM b-Mercaptoethanol.
Flow cytometry and confocal microscopy
The N-GFP and GFP were quantified on a Coomassie blue-
stained SDS-PAGE using ImageJ software and a dilution range of
BSA as standards. RAW and D2SC/1 cells were incubated in D-
PBS (Gibco) supplemented with 5 mM EDTA, 0.33% lidocaine
(Astra Zeneca) for 2 min at 37uC and centrifuged for 7 min at
500 g. The pellet was resuspended in PBS supplemented with 2%
FCS. Viable cells were adjusted to 10
7 cells/mL and incubated in
round bottom tubes with 30 mM GFP or N-GFP SRS for one hour
at 37uC together with propidium iodide at a final concentration of
1 mg/ml. The association of GFP with cells was then analyzed by
flow cytometry using a FACS Calibur (Becton Dickinson). Data
analysis was performed on 50,000 events with Cell Quest Pro
software (Becton Dickinson). Dead cells were excluded on the basis
of propidium iodide labeling.
For confocal microscopy examination, cells treated following
the same protocol but without addition of PI, were fixed,
permeabilized using the ‘‘Fix and Perm’’ kit (Caltag) according
to the manufacturer instructions, and stained with 0.4 U/mL
phalloidin-rhodamin (Molecular Probes). After 15 min incubation,
cells were resuspended in PBS supplemented with 2% FCS, and
10
5 cells were centrifuged (Cytospin 2, Chandons) on Superfrost
plus slides (SFPLUS-42, Milian) and mounted in Fluoromount G
(InterBio Tech). Dual-immunofluorescence confocal images were
acquired with a confocal laser scanning microscope (LSM 510
META, Zeiss) equiped with a Plan-Achromat 636oil immersion
objective (1.4 numerical aperture). Stacks of confocal images were
acquired at 0.37 mm intervals. Images were processed using Zeiss
LS Image Browser software for overlays of red and green channels.
Vaccine formulation and virus
The detoxified E. coli enterotoxin LT(R192G) was provided
endotoxin free by Prof. Clements (Tulane University, New
Orleans, USA). Purified N SRS had an endotoxin content of 1–
3 EU/mg protein (QCL-1000 LAL assay, Cambrex).
The RSV strain A2 (provided by Prof. Openshaw, Imperial
College, Saint Mary’s Hospital, London) was propagated and
titrated by plaque assay on HEp-2 monolayers.
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Eight- to 10-week-old BALB/c female mice were purchased
from Charles River Laboratories (Lyon, France) and bred under
specific pathogen-free conditions in the INRA animal care
facilities (Jouy-en-Josas, France). All animal experiments were
carried out under the authority of licence issued by the Direction
des Services Ve ´te ´rinaires (accreditation number 78-27).
Anaesthetized mice were immunized intra-nasally twice, two
weeks apart, with 10 mg N SRS and/or 5 mg LT(R192G) in 50 mL
0.9% apyrogen NaCl. In some experiment mice were vaccinated
sub-cutaneously. For viral challenge, mice were infected intra-
nasally with 10
7 PFU RSV-A2, two weeks after the booster
immunization. Their weight was monitored daily up to euthana-
sia. Sera were obtained from blood collected via retro-orbital
punction at day 0, 14 and 28 post-immunization or just before
killing by cervical dislocation at 4–10 days post-infection. Lymph
nodes draining the upper respiratory tract (cervical and maxilliary
LN) and spleen were dissected out. The bronchus connected to the
left lobe of the lung was clamped. The left lobe of the lung was
snap frozen in liquid nitrogen and kept frozen at 280uC until
extraction of RNA for RT-PCR. To collect broncho-alveolar
lavage fluids (BAL), the mouse trachea was surgically exposed,
cannulated with a syringe and the remaining lobes of the lungs
were flushed four times in and out using 1.5 mL D-PBS (Gibco)
supplemented with 1mM EDTA (Gibco). After centrifugation
(4 min, 500g), viable BAL cells were resuspended at appropriate
concentration for cytocentrifugation. Sera and BAL supernatants
were stored frozen at 220uC. For histological analysis, the lungs
were inflated via the trachea with 1 mL of PBS with 4%
paraformaldehyde and 2% saccharose, dissected out and im-
merged into PBS, 4% PFA and 2% saccharose for a week, then
dehydrated and embedded in paraffin.
Determination of pulmonary RSV load by Real-time PCR
Frozen lungs were homogenized directly in lysis buffer
(Absolutely RNA miniprep kit, Stratagene) using RNAse free
microtubes and pellet pestle (Kimble-Kontes). Total lung
RNA was extracted using the Absolutely RNA miniprep kit
(Stratagene). Total RNA amount was quantified at 260 nm.
Of each RNA sample, 1 mg were reverse transcribed for one hour
at 42uC, using 300 U of M-MLV Reverse Transcriptase
(SuperScript II, Invitrogene) with 7 mM of random hexanucleotide
primers (pd(N)6, Pharmacia Biotech), 15 nmol of each dNTP,
5 mM DTT and 60 U of ribonuclease inhibitor (RNAseOUT,
Invitrogen). The quality and relative amount of cDNA was
assessed by semi-quantitative PCR for b-actine as previously
described [50].
Quantitative real time-PCR was performed targeting the
conserved region of the RSV-N gene as described by Chavez-
Bueno [51]. Briefly, a 84 bp amplification product corresponding
to positions 42 to 125 of the N gene from the hRSV-A2 strain was
obtained using the AGATCAACTTCTGTCATCCAGCAA up-
stream and the TTCTGCACATCATAATTAGGAGTATCAAT
downstream primers. Q-PCR was run on a Perkin Elmer ABI
Prism 7700 Sequence Detector, using the SYBR GREEN PCR
Master Mix (Applied Biosystems) and 300 nM of each primer.
cDNA samples were run in triplicate (111 ng per reaction) as well
as non template controls. In each assay, serial ten fold dilutions of
the plasmid pET-N were run in duplicate, allowing to quantify the
number of N gene copies generated from unknown samples by
comparison of the cycle threshold values using the SDS 1.9.1
software. Results were expressed as the number of copies of N
RNA per mg of input total lung RNA. The detection limit of the
PCR method was calculated according to the cycle threshold
values of non-infected control lungs and the highest dilution of
pET-N giving the same cycle threshold value. We estimated the
detection limit of our assay to be 20 copies of N per mg of input
total lung RNA.
May-Gru ¨nwald-Giemsa staining and histology
Macrophages, lymphocytes, neutrophils and eosinophils were
enumerated by microscopic examination of May-Gru ¨nwald and
Giemsa stained cytocentrifuge slides. At least 300 cells/sample
were counted.
Lung sections (7 mm) were prepared from paraffin-embedded
tissue using a microtome and stained with hematoxylin and eosin.
Flow cytometry analysis of BAL lymphocytes
After a first 20 min incubation with anti-CD32/CD16 (FcBlock,
BD bioscience), BAL cells were stained with anti-CD4-FITC, anti-
CD8-Biot and anti-CD69-PE conjugated rat anti-mouse Abs (BD
bioscience) for 30 min on ice, washed and then incubated for
another 30 min on ice with streptavidin-APC (BD bioscience).
Cells were then fixed in 10% CellFIX (BD bioscience). All samples
were analyzed on a FACScalibur (BD Biosciences) collecting data
on at least 5,000 lymphocytes gated according to their forward and
side scatter features.
CFSE staining of splenocytes and CD8/CD4-proliferation
assay
Freshly isolated, red blood cells depleted splenocytes were
incubated with 2 mM CFSE (Molecular Probes) in RPMI without
FCS for 10 min at 37uC and then co-cultured for 7 days as
described above (section 4.9) with either N SRS (10 mg/mL final
concentration), hRSV-A2 (1 PFU/cell) or with medium alone as
negative control all diluted in RPMI 1640 supplemented with 10%
FCS, PS, 2mM L-glutamine and 50 mM b2-mercaptoethanol
(Sigma). After a first 20 min incubation with anti-CD32/CD16
(FcBlock, BD bioscience), CFSE-labeled splenocytes were stained
with an anti-CD8-Biot and with an anti-CD4-PE (BD bioscience)
for 30 min on ice, washed and then incubated for another 30 min
on ice with streptavidin-APC (BD bioscience). Cells were then
fixed in 10% CellFIX (BD bioscience) and analyzed on a
FACScalibur (BD Biosciences) collecting 100,000 events. Prolifer-
ating cells were characterized as CFSE
low. As expected CFSE
low
lymphocytes displayed higher FSC and SSC parameters than their
non-dividing CFSE
high counterpart.
IFN-c production by immune spleen or lymph node cells
Individual spleens and pooled lymph nodes were minced and
mashed gently through a 100 mm nylon filter (Falcon). Red blood
cells depleted splenocytes and lymph node cells were adjusted to
2.10
6 viable cells/mL in RPMI 1640 supplemented with 10%
FCS, PS and 2 mM L-glutamine and 4.10
5 cells/well were
distributed in 96-well flat-bottomed microtiter plates (Falcon
3072). Cells were then incubated in triplicates with either N
SRS (10 mg/mL final concentration) or, as negative control, with
medium alone or, as positive control, with 10 ng/mL PMA
(Phorbol 12-myristate 13-acetate, Sigma) and 1 mg/mL Ionomy-
cin (Calbiochem). Cell cultures were incubated at 37uCi n5 %
CO2 for 72 hr, and supernatants were harvested and kept frozen
at 220uC until assayed.
Supernatants were assayed for IFN-c by a standardized ELISA
using capture MAb R4-6A2 and biotinylated XMG1.2 (BD
biosciences) as previously described [52]. Murine rIFN-c (R&D
systems) diluted from 3300 to 1.5 pg/mL was added in duplicate
wells to establish a standard curve.
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+ and CD8
+
lymphocytes
Splenocytes (10
7 cells) resuspended in D-PBS (Gibco), 1mM
EDTA and 2% FCS, were incubated with 5 mg/mL anti-CD16/
CD32 (FcBlock, BD bioscience), and 1 mg/mL FITC-conjugated
anti-CD4 or anti-CD8a (BD bioscience) for 15 min on ice with
gentle agitation. Cells were washed twice, incubated for 15 min
with the EasySep FITC-selection cocktail and for a further 10 min
with the EasySep magnetic particles before cell separation was
performed according to manufacturer instructions (StemCell
technologies). Approximately 99% CD4
+ or CD8
+ cells were
depleted from the corresponding negative fractions, as assessed by
flow-cytometry using a FACS Calibur.
IFN-c ELISPOT
Millipore 96-wells flat-bottom plates (MAHA S4510, Polylabo)
were incubated overnight at 4uC with 100 mL/well of capture anti-
IFN-c (MAb clone R4-6A2, BD-biosciences) at 10 mg/mL in PBS.
Plates were washed 3 times with sterile PBS and incubated for 2 hr
at 37uC with RPMI 10% FCS to prevent non specific binding. N
antigen (100 mL/well of N SRS at 10 mg/mL in RPMI) was added
to allwellsand then 100 ml of serialdoubling dilutions (startingfrom
2.5610
6 cells/mL) of freshly isolated total, CD4
2 or CD8
2
splenocytes in RPMI 10% FCS, PS, 2 mM L-glutamine and
incubated 20 hr at 37uCi n5 %C O 2. The plates were washed with
ultrapure water and then with PBS and incubated for 2 hr at 37uC
with 100 ml/well of biotinylated anti-IFN-c Mab (clone XMG1.2,
BD biosciences) at 2 mg/mL in PBS supplemented with 0.05%
Tween 20 and 1% BSA. After further washes and 45 min
incubation with ExtrAvidin-alkaline-phosphatase at 1 mg/mL
(Sigma), the IFN-c producing cells were visualized by adding the
substrate BCIP-NBT (Five-bromo-4-chloro-3-indolylphosphate/ni-
trobluetetrazolium; Sigma)in100 mMTris,100 mMNaCl,5 mM
MgCl2, pH=9.5 for 30 min. Results were expressed as the number
of spot-forming cells (SFC) per 10
6 input cells.
N SRS-specific antibody E.L.I.S.A.
Individual mouse sera and BAL supernatants were assayed for
N-specific antibodies (total Ig, IgG2a, IgG1 and IgA) by ELISA.
Microtiter plates (Immulon 2HB, ThermoLabsystems) were coated
overnight at 4uC with N SRS antigen (200 ng per well in 100 mL
carbonate-bicarbonate buffer 0.1 M pH 9.5). Plates were washed
five times with PBS 0.05% Tween 20 between each step of the
assay. After coating, the remaining protein binding sites were
saturated with 5% FCS in PBS 0.05% Tween 20 (PBS-T-FCS) for
1h ra t3 7 uC. Samples were serially diluted threefold in PBS-T-
FCS starting at 1:30 for sera and 1:3 for BAL and incubated for
2 hrs at 37uC. Antigen-bound Abs were detected using HRP-
conjugated goat anti mouse IgH+L (P.A.R.I.S.) or rat anti mouse
IgG1 or IgG2a (BD-Biosciences) or rat anti mouse IgA (Caltag) all
at 1ng/mL, incubated for 1 hr at 37uC. The TMB substrate
(Kirkegaard & Perry Laboratories Inc.) was added and the
reaction was stopped after 10 min by 1M phosphoric acid. The
absorbance was measured at 450 nm with an ELISA plate reader
(Dynex, MRX revelation). The results were expressed as end-point
antibody titers calculated by regression analysis plotting dilution
versus A450 (regression curve y=(b+cx)/(1+ax) using Origin
software). Endpoint titers were calculated as the highest dilution
giving twice the absorbance of negative control.
Alternatively, plates were coated with heat-inactivated frozen-
thawed cellular pellets from RSV-infected or mock-infected HEp-
2 cultures in PBS. Samples were serially diluted and incubated
with RSV-infected and control HEp-2 lysates, and the ELISA was
performed as described above. To measure anti-RSV specific
binding, background antibody binding to control HEp-2 lysate
was deduced from binding to RSV-infected HEp-2.
Data analysis
All data were expressed as arithmetic mean6standard error of
the mean (SEM). Statistical analysis was performed using non
parametric Mann-Whitney U test (http://elegans.swmed.edu/
,leon/stats/utest.html). Levels of significance are indicated on the
graphs with stars: * p,0.05, ** p,0.01.
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